Skip to main
CRL

CRL Stock Forecast & Price Target

CRL Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 46%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

Charles River is setting positive targets for growth, margin improvement, and cost savings through 2030, but faces risks associated with the contract research industry. The company has raised its EPS estimate and price target for 2027, with potential for further growth through strategic initiatives. However, potential risks include changes in government regulations and failure to create value through their strategic review.

Bears say

Charles River is a leading provider of drug discovery and development services, but the company's heavy reliance on animal testing for its research and development processes presents ethical and regulatory risks. Additionally, the company's limited capabilities in non-animal testing methods could lead to revenue erosion if the FDA accepts these methods faster than expected. Furthermore, there are gaps in sustainability integration, such as lack of disclosure on executive compensation tied to sustainability KPIs and limited progress in reducing animal use despite ethical concerns. As of year-end 2025, Charles River's Board of Directors has a high level of diversity, but there are concerns over transparency in animal welfare metrics and progress.

CRL has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 46% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Charles River Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Charles River Laboratories (CRL) Forecast

Analysts have given CRL a Buy based on their latest research and market trends.

According to 13 analysts, CRL has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $297.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $297.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Charles River Laboratories (CRL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.